About us

In 2019, about one million people in Japan were diagnosed with cancer, and many patients continue to suffer despite advances in diagnosis and treatment technologies. Surgical removal is difficult, especially when cancer has metastasized to distant organs, and achieving a complete cure remains challenging even with chemotherapy and radiation therapy. Chemotherapy is administered according to standard treatment guidelines confirmed effective by large-scale clinical trials. However, this does not ensure the best outcomes for all patients. When the chosen anticancer drugs are ineffective, patients face not only further cancer progression but also significant physical and financial burdens due to side effects and high medical costs. We could prevent these issues by predicting each patient’s response to anticancer drugs in advance and selecting the most effective treatment. Based on this idea, our project is developing personalized cancer therapy using live cancer cells derived from patients.